As demand for earlier Alzheimer’s disease (AD) evaluation grows, blood-based biomarkers are helping expand access to diagnostic testing.

This white paper highlights key analytic and clinical considerations for plasma phosphorylated tau 217 (pTau 217) testing, including how cutoff selection directly impacts diagnostic sensitivity and specificity. Understanding these factors is critical to selecting tests that support confident clinical decision-making.

pTau 217 is one of the most informative biomarkers for AD and can be detected in plasma early in the disease process, supporting more timely evaluation.